RecruitingPhase 3NCT05832580

The Prevention of Systemic Ectopic Mineralization in Pseudoxanthoma Elasticum


Sponsor

UMC Utrecht

Enrollment

76 participants

Start Date

Apr 26, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

The goal of this randomized clinical trial is to assess the effect of etidronate on ectopic calcification in relatively young patients with Pseudoxanthoma elasticum. The main question it aims to answer are: What is the difference in the arterial calcification scores in the legs and the carotid syphon measured on low-dose CT scan after 24 months of treatment compared to baseline between etidronate and placebo. Participants will be asked to do take etidronate or placebo for 24 months.


Eligibility

Min Age: 18 YearsMax Age: 50 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Etidronate and a drug called Placebo for people with pseudoxanthoma elasticum. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGEtidronate

Etidronate in capsules of 200 mg or 400 mg.

DRUGPlacebo

Placebo in similar capsules


Locations(1)

University Medical Center Utrecht

Utrecht, Netherlands

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05832580


Related Trials